Bliss GVS Pharma Shareholders Approve Appointment of Two Independent Directors via Postal Ballot

3 min read     Updated on 13 May 2026, 01:09 AM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Bliss GVS Pharma Limited disclosed postal ballot results for two special resolutions appointing Mr. Vijayanarayanan Mahadevan (DIN: 06639177) and Mr. Deepak Rameshchandra Shah (DIN: 06954206) as Non-Executive Independent Directors for five-year terms each. Both resolutions were passed with 99.72% votes in favour out of 5,19,88,637 total votes polled, with nil invalid votes across all shareholder categories. The e-voting process was conducted via CDSL between April 10 and May 09, 2026, with Mr. Vijay Yadav of M/s. AVS & Associates serving as Scrutinizer.

powered bylight_fuzz_icon
40159923

*this image is generated using AI for illustrative purposes only.

Bliss GVS Pharma Limited has disclosed the voting results of its postal ballot conducted through a remote e-voting process, pursuant to Section 108 and Section 110 of the Companies Act, 2013, and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The record date for determining eligible shareholders was April 07, 2026, on which date the total number of shareholders stood at 45,804. Two special resolutions were put to vote, both concerning the appointment of Non-Executive Independent Directors for a term of five years each.

Postal Ballot Process and Scrutinizer's Report

The Board of Directors of Bliss GVS Pharma appointed Mr. Vijay Yadav (FCS - 11990), Partner of M/s. AVS & Associates, Company Secretaries, as the Scrutinizer for the postal ballot and e-voting process via a circular resolution passed on April 03, 2026. The e-voting facility was provided by Central Depository Services (India) Limited (CDSL). The voting period commenced on Friday, April 10, 2026 (09:00 A.M. IST) and concluded on Saturday, May 09, 2026 (05:00 P.M. IST). The Scrutinizer submitted his report to the Company on May 11, 2026, and the results were disclosed on May 12, 2026.

Resolution 1: Appointment of Mr. Vijayanarayanan Mahadevan as Independent Director

The first special resolution pertained to the appointment of Mr. Vijayanarayanan Mahadevan (DIN: 06639177) as a Non-Executive Independent Director for a term of five years. The promoter and promoter group were not interested in this resolution. The detailed voting outcome is presented below:

Category: Shares Held Votes Polled % Polled Votes in Favour Votes Against % in Favour % Against
Promoter & Promoter Group 3,74,04,297 3,45,79,212 92.45 3,45,79,212 0 100.00 0.00
Public Institutions 1,55,11,459 24,46,266 15.77 23,01,863 1,44,403 94.10 5.90
Public - Non Institutions 5,28,73,216 1,49,63,159 28.30 1,49,62,457 702 100.00 0.00
Grand Total 10,57,88,972 5,19,88,637 49.14 5,18,43,532 1,45,105 99.72 0.28

The resolution was passed, with 99.72% of votes polled cast in favour. There were no invalid votes recorded across any shareholder category.

Resolution 2: Appointment of Mr. Deepak Rameshchandra Shah as Independent Director

The second special resolution concerned the appointment of Mr. Deepak Rameshchandra Shah (DIN: 06954206) as a Non-Executive Independent Director for a term of five years. The promoter and promoter group were not interested in this resolution either. The voting results are as follows:

Category: Shares Held Votes Polled % Polled Votes in Favour Votes Against % in Favour % Against
Promoter & Promoter Group 3,74,04,297 3,45,79,212 92.45 3,45,79,212 0 100.00 0.00
Public Institutions 1,55,11,459 24,46,266 15.77 23,01,863 1,44,403 94.10 5.90
Public - Non Institutions 5,28,73,216 1,49,63,159 28.30 1,49,62,379 780 99.99 0.01
Grand Total 10,57,88,972 5,19,88,637 49.14 5,18,43,454 1,45,183 99.72 0.28

This resolution was also passed, with 99.72% of votes polled cast in favour. No invalid votes were recorded in any category.

Key Highlights of the Postal Ballot

  • Record Date: April 07, 2026
  • Total Shareholders on Record Date: 45,804
  • Voting Period: April 10, 2026 (09:00 A.M. IST) to May 09, 2026 (05:00 P.M. IST)
  • E-voting Platform: Central Depository Services (India) Limited (CDSL)
  • Scrutinizer: Mr. Vijay Yadav, Partner, M/s. AVS & Associates, Company Secretaries (FCS - 11990, COP No: 16806)
  • Scrutinizer's Report Date: May 11, 2026
  • Total Resolutions Passed: 2
  • Invalid Votes: Nil across all categories for both resolutions

The voting results and the Scrutinizer's report have been uploaded on the Company's website at www.blissgvs.com . The disclosure was submitted to the National Stock Exchange of India and BSE Limited on May 12, 2026, and was signed by Aditi Bhatt, Company Secretary of Bliss GVS Pharma Limited.

Historical Stock Returns for Bliss GVS Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+3.52%+8.01%+10.89%+72.85%+144.12%+156.56%

How might the newly appointed independent directors, Mr. Mahadevan and Mr. Shah, influence Bliss GVS Pharma's strategic direction, particularly in areas like international expansion or regulatory compliance?

Given that only ~49% of total shares were polled in this ballot, what measures could Bliss GVS Pharma take to improve shareholder participation in future governance decisions?

With two new independent directors joining the board for five-year terms, how could this strengthen Bliss GVS Pharma's corporate governance framework and potentially attract institutional investors?

Bliss GVS Pharma Board Meeting Scheduled on May 12, 2026 to Approve Q4 FY26 Results and Final Dividend

1 min read     Updated on 06 May 2026, 01:11 AM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Bliss GVS Pharma has scheduled a Board of Directors meeting on May 12, 2026, to approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a final dividend for FY26. In compliance with SEBI insider trading regulations, the trading window for Designated Persons has been closed from April 01, 2026, and will remain shut until 48 hours after the financial results are declared.

powered bylight_fuzz_icon
39555702

*this image is generated using AI for illustrative purposes only.

Bliss GVS Pharma has informed the stock exchanges of a scheduled Board of Directors meeting on Tuesday, May 12, 2026, at its registered office. The intimation has been filed pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting has been convened to consider and approve key financial matters pertaining to the quarter and full financial year ended March 31, 2026.

Agenda for the Board Meeting

The board meeting has been called to deliberate on the following key items, as outlined in the regulatory filing:

Agenda Item: Details
Financial Results: Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026
Additional Statements: Statement of Assets and Liabilities, Cash Flow Statement, and Audit Report (with modified opinion, if any)
Financial Statements: Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026
Dividend Consideration: Recommendation of Final Dividend, if any, for the financial year ended March 31, 2026

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Company's Code of Internal Procedures and Conduct for Regulating, Monitoring, and Reporting of Trading by Designated Persons, the trading window for dealing in shares of Bliss GVS Pharma has been closed for all Designated Persons and their immediate relatives. The closure took effect from April 01, 2026, and will remain in force until 48 hours after the announcement or declaration of the audited financial results for the quarter and year ended March 31, 2026, or until the information becomes generally available.

The intimation has been signed by Aditi Bhatt, Company Secretary, and has also been uploaded to the Company's official website at https://www.blissgvs.com/corporate-announcement .

Historical Stock Returns for Bliss GVS Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+3.52%+8.01%+10.89%+72.85%+144.12%+156.56%

Will Bliss GVS Pharma declare a final dividend for FY2026, and how does its dividend history suggest the likelihood and potential yield for shareholders?

How might Bliss GVS Pharma's audited FY2026 financial results compare to analyst expectations, and what key metrics should investors watch for signs of business recovery or growth?

If the audit report carries a modified opinion, what impact could that have on investor confidence and the company's stock performance in the near term?

More News on Bliss GVS Pharma

1 Year Returns:+144.12%